CN112584857A - 卡那吉努单抗的用途 - Google Patents

卡那吉努单抗的用途 Download PDF

Info

Publication number
CN112584857A
CN112584857A CN201880094285.6A CN201880094285A CN112584857A CN 112584857 A CN112584857 A CN 112584857A CN 201880094285 A CN201880094285 A CN 201880094285A CN 112584857 A CN112584857 A CN 112584857A
Authority
CN
China
Prior art keywords
patient
hscrp
antagonist
assessed
canakinumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880094285.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·希克
L·明德霍尔姆
J·普雷斯加德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202411634666.2A priority Critical patent/CN119746057A/zh
Publication of CN112584857A publication Critical patent/CN112584857A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880094285.6A 2018-05-09 2018-08-24 卡那吉努单抗的用途 Pending CN112584857A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411634666.2A CN119746057A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09
US62/669,071 2018-05-09
PCT/IB2018/056455 WO2019215484A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411634666.2A Division CN119746057A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Publications (1)

Publication Number Publication Date
CN112584857A true CN112584857A (zh) 2021-03-30

Family

ID=63638190

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880094285.6A Pending CN112584857A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途
CN202411634666.2A Pending CN119746057A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411634666.2A Pending CN119746057A (zh) 2018-05-09 2018-08-24 卡那吉努单抗的用途

Country Status (12)

Country Link
US (1) US20210371511A1 (https=)
EP (1) EP3790576A1 (https=)
JP (2) JP2021523894A (https=)
KR (1) KR20210008847A (https=)
CN (2) CN112584857A (https=)
AU (1) AU2018422406A1 (https=)
BR (1) BR112020022576A2 (https=)
CA (1) CA3098277A1 (https=)
CL (1) CL2020002881A1 (https=)
MX (1) MX2020011909A (https=)
TW (1) TW201946652A (https=)
WO (1) WO2019215484A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
CN103189074A (zh) * 2010-11-05 2013-07-03 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
US20140356356A1 (en) * 2011-09-30 2014-12-04 Novartis Ag Use of IL-1 beta Binding Antibodies
US20150203592A1 (en) * 2013-12-02 2015-07-23 Abbvie Inc. Compositions and methods for treating osteoarthritis
CN107723310A (zh) * 2017-10-19 2018-02-23 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用
CN110730788A (zh) * 2017-06-12 2020-01-24 诺华股份有限公司 制造双特异性抗体的方法，双特异性抗体和此类抗体的治疗用途
CN110831967A (zh) * 2017-06-22 2020-02-21 诺华股份有限公司 用于治疗癌症的IL-1β结合抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
PL1940465T3 (pl) * 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016436A2 (en) * 2000-08-22 2002-02-28 Novartis Ag ANTIBODIES TO HUMAN IL-1$g(b)
CN1484652A (zh) * 2000-08-22 2004-03-24 ��˹��ŵ�� 人IL-1β的抗体
CN103189074A (zh) * 2010-11-05 2013-07-03 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
US20140356356A1 (en) * 2011-09-30 2014-12-04 Novartis Ag Use of IL-1 beta Binding Antibodies
US20150203592A1 (en) * 2013-12-02 2015-07-23 Abbvie Inc. Compositions and methods for treating osteoarthritis
CN110730788A (zh) * 2017-06-12 2020-01-24 诺华股份有限公司 制造双特异性抗体的方法，双特异性抗体和此类抗体的治疗用途
CN110831967A (zh) * 2017-06-22 2020-02-21 诺华股份有限公司 用于治疗癌症的IL-1β结合抗体
CN107723310A (zh) * 2017-10-19 2018-02-23 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NOVARTIS: "To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee.", pages 01160822, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/show/study/NCT01160822> *
SARA CHELESCHI 等: "Possible chondroprotective effect of canakinumab: An in vitro study on human osteoarthritic chondrocytes", CYTOKINE, pages 165 - 172 *
T. D. SPECTOR 等: "LOW-LEVEL INCREASES IN SERUM C-REACTIVE PROTEIN ARE PRESENT IN EARLY OSTEOARTHRITIS OF THE KNEE AND PREDICT PROGRESSIVE DISEASE.", ARTHRITIS & RHEUMATISM, 30 April 1997 (1997-04-30), pages 723 - 727 *

Also Published As

Publication number Publication date
JP2023071904A (ja) 2023-05-23
KR20210008847A (ko) 2021-01-25
JP7713983B2 (ja) 2025-07-28
AU2018422406A1 (en) 2020-11-12
CN119746057A (zh) 2025-04-04
US20210371511A1 (en) 2021-12-02
EP3790576A1 (en) 2021-03-17
BR112020022576A2 (pt) 2021-02-09
TW201946652A (zh) 2019-12-16
JP2021523894A (ja) 2021-09-09
MX2020011909A (es) 2021-01-29
CL2020002881A1 (es) 2021-05-14
WO2019215484A1 (en) 2019-11-14
CA3098277A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
Manicourt et al. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis
US20200368247A1 (en) Cenicriviroc for the treatment of fibrosis
Chapman et al. Use of a radiolabeled monoclonal antibody against E‐selectin for imaging of endothelial activation in rheumatoid arthritis
Rump et al. An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium
Dairaghi et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose
JP2021503476A (ja) Ｉｌ−１７アンタゴニストを用いて化膿性汗腺炎を治療すること
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
Gazda et al. Clinical outcomes of tocilizumab therapy in polyarticular and systemic juvenile idiopathic arthritis: a single-center analysis (2018-2022)
JP7713983B2 (ja) カナキヌマブの使用
Crook et al. The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease
WO2022167916A1 (en) Use of il-1b binding antibodies for treating neuroinflammatory disorders
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
US10676522B2 (en) Methods of selectively treating asthma using IL-17 antagonists
WO2025225719A1 (en) Treatment and prevention of muscular dystrophy and its related diseases or disorders with satralizumab
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
Morgado Internship Reports and Monograph Entitled “Pharmacokinetic Monitorization of Monoclonal Antibodies: The Example of Infliximab in Inflammatory Bowel Diseases”
JP2025500352A (ja) Ｉｌ－１８に対する抗体を要する成人発症スチル病および全身発症型若年性特発性関節炎のための方法および治療
Kondo et al. THU0577 Tocilizumab monotherapy for adult onset still's disease–results of 52-week treatment of a prospective, single-center, single-arm, open trial
Espinosa et al. Pediatric Rheumatology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination